Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Net Income towards Common Stockholders (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Net Income towards Common Stockholders for 15 consecutive years, with -$7.2 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 38.75% to -$7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.9 million through Dec 2025, down 0.93% year-over-year, with the annual reading at -$45.9 million for FY2025, 0.93% down from the prior year.
  • Net Income towards Common Stockholders hit -$7.2 million in Q4 2025 for Cardiff Oncology, up from -$11.3 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.2 million in Q1 2021 to a low of -$13.9 million in Q2 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$10.0 million across 5 years, with a median of -$10.2 million in 2022.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 112.13% in 2022 and later surged 38.75% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$9.4 million in 2021, then grew by 7.89% to -$8.7 million in 2022, then fell by 7.35% to -$9.3 million in 2023, then dropped by 26.22% to -$11.8 million in 2024, then soared by 38.75% to -$7.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CRDF at -$7.2 million in Q4 2025, -$11.3 million in Q3 2025, and -$13.9 million in Q2 2025.